公开(公告)号：US20230233613A1

公开(公告)日：2023-07-27

申请号：US17963219

申请日：2022-10-11

Applicant: Gwo Xi Stem Cell Applied Technology Co., Ltd.

Inventor： Po-Cheng Lin ,  Pi-Chun Huang ,  Chia-Hsin Lee ,  Ming-Hsi Chuang ,  Chun-Hung Chen ,  Chao-Liang Chang ,  Kai-Ling Zhang ,  Yi-Chun Lin ,  Yu-Chen Tsai ,  Peggy Leh Jiunn Wong ,  Ruei-Yue Liang

IPC: A61K35/28 ,  A61K9/00 ,  C12N5/0789

CPC classification number: A61K35/28 ,  A61K9/0085 ,  A61K9/0019 ,  C12N5/0647 ,  C12N2501/10 ,  C12N2502/1382 ,  C12N2501/2304 ,  C12N2501/2313

Abstract: The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising TS stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the TS stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

公开(公告)号：US20240115616A1

公开(公告)日：2024-04-11

申请号：US18376545

申请日：2023-10-04

Applicant: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.

Inventor： Po-Cheng Lin ,  Pi-Chun Huang ,  Zih-Han Hong ,  Ming-Hsi Chuang ,  Yi-Chun Lin ,  Chia-Hsin Lee ,  Chun-Hung Chen ,  Chao-Liang Chang ,  Kai-Ling Zhang

IPC: A61K35/28 ,  A61K9/00 ,  A61K9/127 ,  A61P1/16 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A61K9/0019 ,  A61K9/127 ,  A61P1/16 ,  C12N5/0667 ,  C12N2500/02

Abstract: The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.